NCT05049629

Effect of Chitosan-N-Acetylcysteine on IOL-power Prior to Cataract Surgery

Effect of Chitosan-N-Acetylcysteine (Lacrimera®) on IOL-power Prior to Cataract Surgery: a Pilot Study

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Vienna Institute for Research in Ocular Surgery · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Aim of this study is to evaluate the effect of treatment with Lacrimera® on calculated IOL power prior to cataract surgery and on the stability of ocular surface parameters compared to preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).

Detailed description

The present study seeks to investigate the effect of treatment with Lacrimera® on the calculated IOL power prior to cataract surgery and on the stability of ocular surface parameters compared to preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).

Conditions

• Eye Diseases

Interventions

Type	Name	Description
DEVICE	Lacrimera	A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
DEVICE	Hylo-Vision	Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine)

Timeline

• Start date: 2021-05-12
• Primary completion: 2021-08-31
• Completion: 2021-08-31
• First posted: 2021-09-20
• Last updated: 2021-09-20

Locations

1 site across 1 country: Austria